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Abstract
Background: Despite widespread use, optimum choice of antimicrobial agents, concentrations, combinations and
exposure times have not been determined for antibiotic lock technique (ALT). Our objective was to evaluate the
efficacy of different antibiotic combinations using an in vitro model of catheter-related infection. Daptomycin (DAP)
5 mg/mL, teicoplanin (TEC) 5 mg/mL, both alone and combined with gentamicin (GM) 2.5 mg/mL, clarythromycin
(CLA) 5 mg/mL or ethanol 35 % were evaluated against four clinical strains of methicillin resistant coagulase negative
staphylococci. Lock solutions were renewed every 24 h.
Results: After 72 h catheters were reincubated with culture media to investigate bacterial regrowth. All antibiotic
combinations resulted in significant reductions (p < 0.05) of Log(10) cfu/mL at 72 h for both organisms compared
with controls. DAP resulted in significant reductions of Log(10) for all organism versus TEC (p = 0.001). Only DAP
reached the limit of detection at 72 h, however did not prevent regrowth after 24 h of ALT removal. DAP + Ethanol
and TEC + ethanol eradicated biofilm at 72 h, but only DAP + ethanol (against all strains) and DAP + CLA (against two
strains) prevented regrowth at 24 h after ALT removal.
Conclusions: Based on these data, ALT with DAP + ethanol and DAP + CLA should be explored in clinical trials.
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Background
Recent reports indicate that central line associated
bloodstream infections (CLA-BSIs) are responsible of
considerable burden of illness in many countries, with a
pooled prevalence of 4,9 per 1000 central line days in
ICUs from Latin America, Asia, Africa and Europe [1].
Many microorganisms can develop biofilms on central
venous catheters And therefore be responsible of cen-
tral line associated bloodstream infections (CLA-BSIs),
although the most commonly isolated microorganism
from hospital-acquired central line associated bloodstream
infections (CLA-BSIs), accounting for almost 35 % of
cases, are coagulase-negative staphylococci (CoNS) [2].
Among CoNS, Staphylococcus epidermidis (SE) is re-
sponsible of a great number of those infections [3].
Pathogenesis of CLA-BSIs has been extensively reviewed;
intraluminal or extraluminal surface colonization of cathe-
ters, subsequent biofilm formation, dispersal and entry
into the bloodstream are the classical steps described in
CLA-BSIs development [4–6].
Current guidelines recommend removal of catheters
in CLA-BSIs due to S. aureus however, antibiotic lock
therapy (ALT) could be used in other staphylococcal CLA-
BSIs provided sepsis, endocarditis, suppurative thrombo-
phlebitis or other septic complications have been excluded
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[7, 8]. During ALT the lumen is filled with a highly concen-
trated antibiotic solution and allowed to dwell (lock) for a
period of time to eradicate bacteria embedded in the intra-
luminal biofilm of the catheter [4]. Since 1980s several au-
thors have reported case series regarding efficacy of ALT
against different microorganisms, and although there are
some comprehensive reviews on this topic [9, 10], its utility
is still a matter of debate. Recent efforts have been made to
overcome this paucity of data, but apart from the need of
randomized controlled trials no other conclusions have
been obtained [11].
Similarly, experimental evidence for the selection of
antimicrobials, alone or in combination is scarce and
limited to a 24–48 h period without further evaluation
of the persistence of biofilm, limiting the interpretation
of results [12–17].
To overcome some of these limitations we com-
pared daptomycin and teicoplanin alone, and in com-
bination with clarithromycin, gentamicin and ethanol,
using an in vitro catheter model that evaluates their
activity in a catheter lock solution by quantifying
antimicrobial kill after 72 h of catheter-lock therapy.
Both drugs are antibacterial agents with documented
efficacy as catheter lock solutions [12, 18–20]. In
addition, to evaluate relapse of infection we allowed
catheters to dwell without antibiotic for another 24 h,
simulating clinical practice of reutilization of central
line after ALT.
Results and discussion
Isolates were susceptible to daptomycin (MIC = 0.25 mg/L
for all isolates) and to teicoplanin (MIC = 1 mg/L for 1022
and MIC = 2 mg/L for 1018, 1076, and 1098) and resistant
to oxacillin (MIC > 1024 mg/L for all isolates), gentamicin
(MIC > 32 mg/L for all isolates) and to clarithromycin
(MIC > 128 mg/L for all isolates).
All antibiotic combinations resulted in significant re-
ductions (p < 0.05) of Log10CFU/mL at 72 h compared
with control. Among single-agent regimens, daptomycin
resulted in significant reductions of Log10CFU/mL ver-
sus teicoplanin (p = 0.001) for all strains tested, however,
neither daptomycin nor teicoplanin were able to reduce
Log10CFU/mL below the limit of detection at 72 h, and
full regrowth was observed after 24 h of ALT removal.
Regarding combinations, daptomycin plus ethanol or
clarithromycin and teicoplanin plus ethanol or clarithro-
mycin were able to eradicate biofilm at 72 h but only
daptomycin plus ethanol against all strains and dapto-
mycin plus clarithromycin against two strains prevented
regrowth after ALT removal and reincubation with ster-
ile fresh media (Table 1, Figs. 1, 2, 3 and 4).
Despite full regrowth of all CoNS after ALT removal
no emergence of resistance was detected against any of
the antibiotics tested.
In our study we found ethanol and clarithromycin
combinations more efficacious than monotherapy with
either daptomycin or teicoplanin. Although monother-
apy reached the limit of detection at 72 h against some
strains, only daptomycin plus ethanol or clarithromycin
prevented regrowth after ALT discontinuation.
Main objective of ALT is catheter salvage, allowing for
reutilization of the catheter after discontinuation of ALT.
If complete eradication has not been achieved, bacterial
regrowth and resurgence of clinical infection are likely to
occur. In our study, in an attempt of mimicking clinical
practice, we introduced a 24 h dwell period with fresh
media after ALT removal.
Although many authors have reported eradication of
microorganisms after ALT with daptomycin, vancomycin
or linezolid, because relapse after ALT was not evaluated,
their results cannot be extrapolated to clinical practice
[12, 15, 21]. In our study, daptomycin alone (against one
Table 1 Mean bacterial count recovered from the in vitro catheter model at different time-points
1018 1022 1076 1098
Atimicrobial regimen t = 0 t = 72 t = 96 t = 0 t = 72 t = 96 t = 0 t = 72 t = 96 t = 0 t = 72 t = 96
Control 8,017 9,02 8,97 7,92 8,67 9,02 7,82 8,45 8,83 7,83 9,12 9,16
Teicoplanin 8,02 4,45* 6,72 7,09 4,03* 6,57 7,04 3,94* 7,44 7,89 3,84* 6,32
Teicoplanin + gentamycin 8,03 5,12* 7,01 7,43 4,5* 6,59 7,52 3,22* 6,67 7,78 2,64* 5,29
Teicoplanin + ethanol 7,94 1* 4,45* 7,85 1* 2,3* 7,27 1* 3,43 7,93 1* 4,02*
Teicoplanin + clarithromycin 7,95 1,89* 4,23* 7,86 1,23* 4,32* 7,29 1* 3,04 7,82 1,78* 5,38
Daptomycin 8,24 2,87*, ** 4,89* 7,33 1*, ** 3,77* 7,32 2,54* 5,48 7,82 3,62* 5,92
Daptomycin + gentamycin 8,12 2,03*, ** 5,67 7,51 3,69* 6,46 7,12 2,12* 4,92* 8,01 1,96* 5,01
Daptomycin + ethanol 7,98 1* 1*, ** 7,79 1* 1*, ** 7,027 1* 1*, ** 8,01 1* 1*, **
Daptomycin + clarithromycin 8,34 1,45* 4,67* 7,95 1* 1*, ** 7,57 1* 1*, ** 7,83 1* 3,84*
Data expressed as Log10CFU/mL
T = 0: baseline. T = 72: end of antibiotic lock therapy. T = 96 h: after reincubation with sterile fresh media
*p < 0.05 versus control
**p < 0.05 vs teicoplanin (alone or in each combination compared against the same combination)
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strains) and some teicoplanin combinations achieved the
limit of detection at 72 h but without complete eradi-
cation of biofilm. On the contrary, daptomycin plus
clarithromycin (against two strains) and daptomycin
plus ethanol (against all strains) maintained eradication
after 24 h of ALT removal and re-incubation with fresh
media, suggesting a potential role in salvage of infected
catheters with a low rate of relapse.
A recent metanalysis support the use of ALT as ad-
junctive therapy in CLA-BSIs [11], however, a 20 %
rate of relapse was observed in patients treated with
ALT despite negative blood cultures drawn at the end
of therapy. This high rate of relapse suggests the per-
sistence of biofilm-embedded bacteria not detected im-
mediately after end of therapy. Our results, negativization
at 72 h, but regrowth after 24 h incubation with fresh
media following ALT removal, corroborate what has been
described, and might support the use of clarithromycin
and ethanol combinations. Aumeran et al. reported the
significant decrease of bacterial inoculum of MRSE in an
in vitro model of subcutaneous injection port infection
using daptomycin, vancomycin or ethanol, with a signifi-
cant regrowth after discontinuation of ALT, similar to
what we found [22]. Although they used a different meth-
odology, the similarity of our results suggest that our
hypothesis is true and relapse of CLA-BSIs is related to
biofilm persistence despite negative blood-cultures drawn
from the catheter after ALT.
Chaudhury et al. reported the efficacy of ethanol at 20,
40 and 80 %, in an in vitro study of MRSA and MRSE
biofilm-associated infection [23]. Ethanol at any of the
concentrations tested was more efficacious than vanco-
mycin, ciprofloxacin and gentamicin in their model of
biofilm-associated infection. Similarly Qu et al. reported
that lock therapy with ethanol at 40 % was more effica-
cious than oxacillin, gentamicin, vancomycin, ciprofloxa-
cin and rifampicin, alone or in combination [24]. We
tested ethanol at 40, 60 and 80 % and found a significant
decrease in Log10CFU/mL but without preventing re-
growth after ALT discontinuation (data not shown). These
Fig. 1 Activity of Teicoplanin (a) and daptomycin (b) alone and in combination against strain 1018
Fig. 2 Activity of Teicoplanin (a) and daptomycin (b) alone and in combination against strain 1022
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preliminary results, similar to those reported by Raad
et al. [25] that reported the inability of ethanol alone to
eradicate an in vitro model of MRSA biofilm or Aumeran
et al. [22], prompted us to explore antibiotic-ethanol
combinations.
Similarly to what Raad et al. reported [25] antibiotic-
ethanol combinations were significantly better than mono-
therapies and prevented regrowth after reincubation.
They found that only ethanol (25 %) plus minocycline
(3 mg/mL) and triple combination of ethanol, mino-
cycline and EDTA (30 mg/mL) were able to eradicate
biofilm and prevent regrowth in a modified Robbins
device. In this silicone disk biofilm colonization model,
although ethanol plus minocycline performed better than
single-regimen therapies and eradicated biofilm, only
triple therapy was able to prevent regrowth. In our study,
the in vitro model of catheter infection was different,
however we obtained very similar results, suggesting that
ethanol plus antibiotics could eradicate biofilm and pre-
vent regrowth after antibiotic lock removal.
Finally, Clarithromycin has shown to interact with bac-
terial biofilms through a non-bactericidal or bacteriostatic
effect. It has been proven to inhibit the production of
hexose, a basic component of staphylococcal biofilms [26].
Many authors have demonstrated this increased activity of
clarithromycin combinations against staphylococcal bio-
films despite no antibacterial activity of clarithromycin
[27–30]. In this study, clarithromycin combinations out-
performed single-regimen therapies. Daptomycin plus clar-
ithromycin prevented regrowth of two strains, suggesting
complete eradication of biofilm. On the other hand, Teico-
planin plus clarithromycin, although reduced the bacterial
burden below the limit of detection, was not able to
prevent regrowth, consistent with a reduced activity of
teicoplanin against MRSE compared to that of daptomycin.
Our study has some limitations. Our protocol allowed
for prolonged dwelling times, a situation that might limit
its reproducibility in clinical practice. However, the fact
that daptomycin plus ethanol and daptomycin plus
clarithromycin (against two strain) were able to eradicate
biofilm after only 72 h could avoid the need for this
prolonged dwelling time. On the other hand, therapies
longer than 3 days could improve our results. Second,
we explored only four MRSE, so our results could not
Fig. 3 Activity of Teicoplanin (a) and daptomycin (b) alone and in combination against strain 1076
Fig. 4 Activity of Teicoplanin (a) and daptomycin (b) alone and in combination against strain 1098
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be extrapolated to all CLA-BSIs, however, as previously
commented, other authors have reported similar results
with ethanol or clarithromycin combinations with dif-
ferent strains [24, 25, 28, 30] which make plausible
that our results could be generalized to MRSE and maybe,
against MRSA, although the latter should be taken with
caution based on paramount differences between CoNs
and Staphylococcus aureus. Third, we did not evaluate the
biofilm forming capability of the MRSE strains. Although
is true that biofilm forming ability is different among
different strains, we have selected four strains isolated
from catheters of patients with documented CLA-BSIs.
This clinical aspect together with the high Log10CFU/mL
recovered prior to any antibiotic challenge suggests high
biofilm forming ability.
Finally we tried to simulate daily clinical practice, so
we chose commercially available drug powders and IV
solutions for human use to make antibiotic lock solu-
tions instead of on analytical powder. Although most
other studies have used analytical drugs powder and so,
our results are not completely comparable, we believe
that our results would have been the same with analyt-
ical powder and, what is more important, they are more
reproducible in clinical practice. Finally, we relied on the
absence of precipitation as an equivalent of drug-stability;
although there can be loss of potency without physical
changes, it is widely accepted that absence of precipitation
is an equivalent of stability and lock solutions can be use
if no physical changes are documented [31–33].
Conclusions
Our study provides strong evidence of the potential of
daptomycin plus ethanol and daptomycin plus clarithro-
mycin to eradicate biofilm and prevent regrowth after
antibiotic lock removal. Although clinical trials should be
performed, our results provide enough rationale support-
ing its use in antibiotic lock technique against MRSE.
Methods
Bacterial isolates
Four clinical isolates of methicillin resistant Staphylococ-
cus epidermidis (MRSE); strains 1018, 1022, 1076, and
1098, recovered from catheters of patients with docu-
mented CLA-BSIs were selected from our collection.
Antibiotics and media
Daptomycin (Cubicin® Novartis Inc. Spain) was generously
provided by the manufacturer. Teicoplanin (Targocid®
Marion-Merrel S.A. Spain), clarithromycin (Klacid® Abbot
Laboratories S.A.), and gentamicin (Normon S.A. Spain)
were commercially purchased as drug powder (Teico-
planin and clarithromycin) or as 20 mg/mL IV solu-
tion (gentamicin). Ethanol was commercially purchased
as 70 % dilution (Lab. Reig Jofré. S.A. Spain). Drug pow-
ders were reconstituted following the CLSI guidelines [34].
Susceptibility testing was performed using e-test
methodology but for DAP that was performed by
microdilution following CLSI guidelines [34]. Mueller
Hinton broth supplemented with 50 μg/ml calcium,
and 12.5 μg/ml magnesium (SMHB) was used for suscep-
tibility testing involving DAP.
Tryptic Soy Broth supplemented with 1 % glucose (TSBg)
was used for biofilm growth.
To evaluate drug stability, each solution was incubated
over 72 h, and then evaluated for physical compatibility
by particulate formation, colour change, or gas evolution
[31–33]. All drug-combinations maintained their initial
conditions and were considered stable.
In vitro model
Test organisms in TSBg at a starting inoculum of
~106 CFU/mL were added to the lumen of an introcan
Safety® 14 Ga × 2 in. catheter (Braun Medical Inc. USA).
Each device was sealed and incubated for 24 h at 35 °C.
After incubation, TSBg was removed and sterile drug-
containing syringes were inserted into access port of the
catheter. Each regimen (sufficient to fill the access port
and full catheter) was slowly injected into each access port
lumen and incubated at 37 °C. Antibiotics lock solutions
were exchanged every 24 h for 72 h. After 72 h, last anti-
biotic lock solution was changed and catheters were filled
again with fresh TSBg and incubated for another 24 h to
reproduce reutilization after ALT.
Catheters were removed at 0, 4, 8, 24, 48, 72 and 96 h.
The lock solution was removed and whole catheters
were placed in a sterile tube filled with 10 mL of saline,
vortexed, sonicated and flushed thoroughly. The bacterial
suspension was then diluted and drop-plated on Tryptic
soy agar (TSA) for bacterial enumeration. The limit of
detection of this method of colony count determination
was 2 Log extended to 1 Log by vacuum filtration.
Bactericidal activity was defined as > 3 Log kill reduction
from initial inoculum at any time point, and emergence of
resistance was assessed by E-test method.
Experiments were performed in triplicate to account
for biological variability. Results are expressed as mean
log10 reduction.
Lock solutions evaluated
Teicoplanin at 5 mg/mL and daptomycin at 5 mg/mL
(diluted in ringer lactate), both alone and in combination
with gentamicin at 2.5 mg/mL, clarithromycin at 5 mg/mL
and ethanol at 35 % were compared. For combination
regimens, final concentrations were tailored to be the
same as for monotherapies. As daptomycin activity is
calcium-dependent, gentamicin and clarithromycin were
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diluted in ringer lactate when combined with daptomycin
and calcium was added to ringer lactate when daptomycin
was combined with ethanol, to maintain the same calcium
concentration in every daptomycin lock solution. Phos-
phate buffered saline (PBS) was used as control.
Statistical analysis
Time to achieve 99.9 % kill (T99.9) was determined by
linear regression (if r2 ≤ 0.95) or visual inspection.
Changes in bacterial CFU/mL were compared by
ANOVA with Tukey’s post-hoc test. A p value < 0.05 was
considered significant.
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